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MET, RON, and SEA are members of a gene family encoding tyrosine kinase receptors with distinctive
properties. Besides mediating growth, they control cell dissociation, motility (“scattering”), and formation of
branching tubules. While there are transforming counterparts of MET and SEA, no oncogenic forms of RON
have yet been identified. A chimeric Tpr-Ron, mimicking the oncogenic form of Met (Tpr-Met) was generated
to investigate its transforming potential. For comparison, a chimeric Tpr-Sea was also constructed. Fusion
with Tpr induced constitutive activation of the Ron and Sea kinases. While Tpr-Sea was more efficient than
Tpr-Met in transformation, Tpr-Ron did not transform NIH 3T3 cells. The differences in the transforming
abilities of Tpr-Met and Tpr-Ron were linked to the functional features of the respective tyrosine kinases using
the approach of swapping subdomains. Kinetic analysis showed that the catalytic efficiency of Tpr-Ron is five
times lower than that of Tpr-Met. Moreover, constitutive activation of Ron resulted in activation of the MAP
kinase signaling cascade approximately three times lower than that attained by Tpr-Met. However, constitutive
activation of Ron did induce a mitogenic-invasive response, causing cell dissociation, motility, and invasion of
extracellular matrices. Tpr-Ron also induced formation of long, unbranched tubules in tridimensional collagen
gels. These data show that RON has the potential to elicit a motile-invasive rather than a transformed
phenotype.
In human malignancies a number of tyrosine kinase recep-
tors are constitutively activated by gene rearrangements that
fuse their kinase domains with N-terminal unrelated sequences
(for a review, see reference 46). The hepatocyte growth factor
(HGF) receptor is converted into an oncogene by rearrange-
ment of the MET proto-oncogene with a gene designated TPR
(6). Similar rearrangements involving TPR have also been re-
ported for RAF and TRK (19, 26). In Tpr-Met the extracellular,
transmembrane, and part of the juxtamembrane domains of
the HGF receptor are replaced by the N-terminal sequence of
Tpr (36). The kinase activity of the resulting hybrid protein is
deregulated, since two leucine-zipper motifs present in the Tpr
moiety promote its constitutive dimerization (17, 41). This
conformation mimics receptor activation following ligand
binding.
A distinctive property of the HGF receptor (Met) is the
ability to evoke a complex response including cell growth,
“scattering,” and tubulogenesis (for a review, see reference 5).
Scattering involves cytoskeletal reorganization and loss of in-
tercellular junctions, followed by active cell migration (14, 16,
55, 61). Epithelial tubulogenesis results from polarized cell
growth and invasion of collagen matrices (33). These pleiotro-
pic effects are elicited by the activation of several signalling
pathways. Met-mediated signal transduction depends on li-
gand-induced phosphorylation of two critical carboxy-terminal
tyrosine residues, which act as docking sites for multiple SH2-
containing cytoplasmic effectors (37).
MET is the prototype of a gene family encoding structurally
related receptors, including human RON (42) and avian SEA
(25). The product of RON has been identified as the receptor
for MSP (macrophage-stimulating protein; 13, 60). MSP was
initially characterized as a macrophage chemotactic factor
(49), but it actually exerts a wider spectrum of biological ac-
tivities, mainly on epithelial and neuroendocrine cells (12).
The human homolog of avian SEA and its specific ligand have
not been identified. It has been demonstrated that Ron and
Sea induce the same array of biological functions as Met:
growth, scattering, and tubulogenesis. The multifunctional
docking site responsible for Met signalling is conserved in the
evolutionary related receptors, suggesting that this motif me-
diates the distinctive biological effects of the members of the
family (32).
The oncogenic form of SEA (sarcoma, erythroblastosis, and
anemia) has been identified as the transforming component of
the avian erythroblastosis S13 retrovirus. The viral transform-
ing gene encodes a 155-kDa transmembrane glycoprotein con-
taining the extracellular and the transmembrane regions of the
viral envelope protein fused with the SEA tyrosine kinase (22,
50).
Constitutively activated forms of RON have not been de-
scribed. To ascertain its oncogenic potential, we generated a
chimeric TPR-RON and transfected it in rodent fibroblasts. In
spite of expressing a constitutive active form of the Ron ty-
rosine kinase, these cells were not transformed. However, Ron
activation induced scatter and invasion of basement mem-
branes in vitro. These data indicate that RON does not behave
as a conventional proto-oncogene and suggest that its activa-
tion may be involved in progression toward the invasive phe-
notype.
MATERIALS AND METHODS
Molecular constructs. Cloning of TPR-MET cDNA has been reported previ-
ously (62). In this chimeric kinase, the first amino acid residue downstream from
the recombination site is an aspartic acid (D-1010) conserved in RON (D-1027)
and SEA (D-1031) sequences. TPR-RON and TPR-SEA constructs were obtained
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by ligation of PCR-amplified fragments at the same junction site, in contiguity
with the conserved D residue. For TPR-RON the forward primer was 59-CCGC
TTCTACCTCGAGGGCCGCTGCCAC-39 designed on 59 untranslated TPR
sequence and the reverse primer was 59-AGGAAAGATATCTGTTAAGTATT
CAAGTTC-3, containing an EcoRV restriction site. The initial codon of the
engineered RON intracellular segment corresponded to the conserved D-1027
residue. This was attained by amplification of the entire RON cDNA template
(13), using the forward 59-CATTCCCGGGCTGGATTCCACCA-39 primer,
containing a SmaI restriction site, and the reverse 59-TCTGTGGAGTGAGGT
ACCTAATG-39 primer. For TPR-SEA the forward primer also matched the
untranslated 59 region of TPR (59-AGCTCGAGAATTCGACATGGCGGCGG
TGTTG-39) and the reverse primer was 59-AGGTCGACTGTTAAGTATTCA
AGTTC-39, containing a SalI restriction site. A modified intracellular region of
SEA, starting with the D-1031 residue, was generated by amplification of a partial
chicken SEA cDNA (kindly provided by T. Parsons, Charlottesville, Va.), using
the forward primer 59-TGCTGCCTGTTGTCGACAGCCCTG-39, containing a
SalI restriction site, and the reverse 59-GGAATTCTCAGCGCACAGCCGCG
TC-39 primer. Tpr-Met/Tpr-Ron swapped constructs were prepared by using the
chimeric cDNAs described above as templates. The recombination sites of the
constructs bearing the swapped juxtamembrane subdomains were generated by
the site-directed mutagenesis system (Promega, Madison, Wis.), inserting the
Tth111I restriction site in position 644 of TPR-MET, with the oligonucleotide
59-CTTCCTATGACTCGGTCATTGAAATGC-39 and by exploiting the native
Tth111I site at position 606 of TPR-RON. The following digestion and ligation
resulted in the replacement of the tyrosine kinase and the C-terminal domains of
Tpr-Met by the counterpart regions of Ron (Tpr-Ron.JM). In parallel, the ty-
rosine kinase and C-terminal domains of Tpr-Ron were exchanged with the same
regions of Tpr-Met (Tpr-Met.JR). The constructs bearing the swapped C-termi-
nal tails were obtained as follows. A SnaBI restriction site was inserted down-
stream from the kinase domain of TPR-MET (position 1446) and of TPR-RON
(position 1533) by PCR amplification. The primer pairs were the forward 59-G
GGGAGCACTACGTACATGTGAAC-39 and the reverse 59-GTTCACATGT
ACGTAGTGCTCCCC-39 in the case of TPR-MET. The forward 59-GGGGAC
CATTACGTACAGCTGCCA-39 and the reverse 59-TGGCAGCTGTACGTA
ATGGTCCCC-39 primers were used in the case of TPR-RON. By recombination
of the SnaBI restriction fragments, the swapping of the C-terminal tails of
Tpr-Met and Tpr-Ron was obtained (Tpr-Ron.CM and Tpr-Met.CR). Finally, the
tyrosine kinase domains were exchanged between Tpr-Met and Tpr-Ron, using
the Tth111I restriction site of Tpr-Ron.CM and Tpr-Ron.JM to obtain the chi-
mera Tpr-Ron.KM and the EcoRV restriction site of Tpr-Met.CR and Tpr-
Met.JR to obtain the chimera Tpr-Met.KR. The fidelity of DNA amplification
was verified by double-stranded DNA sequencing with T7 polymerase (Pharma-
cia, Uppsala, Sweden) according to the dideoxynucleotide methods (45). All
constructs were inserted into the pMT2 eukaryotic expression vector, under
control of the major late adenovirus promoter, and transiently expressed in
COS-1 cells as well as in G418-selected NIH 3T3 mouse embryo fibroblasts.
Cell lines. NIH 3T3 mouse fibroblasts, MDCK cells, and COS-1 cells were
purchased from the American Type Culture Collection. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS) (Sigma Chemical Co., St. Louis, Mo.) and maintained at 378C
in a 5% CO2-humidified atmosphere. NIH 3T3 fibroblasts and MDCK epithelial
stable cell lines expressing the recombinant proteins were obtained by cotrans-
fection of each recombinant plasmid cDNA with pSV2-neo plasmid (ratio of
15:1), using the calcium phosphate precipitation technique (CellPhect, Pharma-
cia, Uppsala, Sweden). The following selection was performed in growth medium
supplemented with 0.8 mg of G418 sulfate (Geneticin; GIBCO BRL Life Tech-
nologies, Inc., Gaithersburg, Md.) per ml. After 2 weeks, the neomycin-resistant
colonies were picked up and expanded into cell lines. Stable cell cultures ex-
pressing the respective recombinant proteins were selected by Western immu-
noblot and in vitro kinase assays, using specific C-terminal antisera. Met, Ron,
and Sea antibodies were raised as described elsewhere (13, 32, 39).
Biochemical assays. Cells (3.5 3 106) were washed twice with cold phosphate-
buffered saline (PBS) and lysed in an ice-cold buffer containing 10 mM PIPES
[piperazine-N,N9-bis(2-ethanesulfonic acid)] (pH 6.8), 100 mM NaCl, 5 mM
MgCl2, 300 mM sucrose, 5 mM EGTA [ethylene glycol-bis(b-aminoethyl ether)-
N,N,N9,N9-tetraacetic acid] (DIM buffer), 1% Triton X-100, 100 mM sodium
orthovanadate, and inhibitors of proteases (aprotinin, 10 mg/ml; pepstatin, 10
mg/ml; leupeptin, 50 mg/ml; soybean trypsin inhibitor, 100 mg/ml; phenylmethyl-
sulfonyl fluoride, 1 mM). The cell lysates were cleared by centrifugation at
15,0003 g for 15 min at 48C. Equal amounts (800 mg) of total proteins from each
cell lines, determined by using the BCA protein assay reagent kit (Pierce, Rock-
ford, Ill.), were immunoprecipitated with stirring for 2 h at 48C with the specific
antisera (anti-Met, anti-Ron, anti-Sea, see above) adsorbed to 30 ml of protein
A-Sepharose 4B packed beads (Pharmacia). The immunocomplexes were
washed twice with lysis buffer, and proteins from immunoprecipitates were sol-
ubilized in boiling Laemmli buffer in reducing conditions. The proteins were
separated on sodium dodecyl sulfate (SDS)–8% polyacrylamide gels and trans-
ferred to nitrocellulose filters (Hybond; Amersham). Filters were probed with
the appropriate antibodies, and specific binding was detected by the enhanced
chemiluminescence system (ECL; Amersham). The in vitro kinase assays were
performed on immunocomplexes (as described above) by incubation in 50 ml of
25 mMHEPES (N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid) (pH 7.4),
5 mM MnCl2, 100 mM dithiothreitol (DTT), in the presence of 40 mM ATP and
10 mCi of [g-32P]ATP (specific activity, .5,000 Ci/mmol; Amersham) for 10 min
at room temperature. The reaction was stopped by adding 1 ml of ice-cold lysis
buffer containing 15 mM EDTA, and the labeled immunocomplexes were eluted
in boiling Laemmli buffer. Labeled phosphoproteins were separated on SDS–8%
polyacrylamide gels and analyzed by autoradiography. In vivo tyrosine autophos-
phorylation was evaluated by Western blotting using phosphotyrosine monoclo-
nal antibodies from Upstate Biotechnology, Inc. (Lake Placid, N.Y.).
Transformation assays. The focus-forming assays were performed on NIH
3T3 fibroblasts (5 3 105 cells) that were cotransfected with 10 mg of each
recombinant plasmid and 0.8 mg of pSV2-neo using the calcium phosphate
precipitation technique (CellPhect; Pharmacia). Twenty-four hours after DNA
transfection the cultures were split at low cell density into 100-mm-diameter
dishes and incubated in DMEM supplemented with 5% FCS. The cell cultures
were maintained at confluence and screened for focus formation 15 to 21 days
later. Spontaneous formation of foci was negligible. To verify the efficiency of
transfection, a fraction of cells were selected in G418-containing medium. Focus-
derived cells and G418-resistant clones were established as stable lines, to verify
chimeric protein expression. The in vitro transforming ability of all constructs
was also assessed by a soft-agar assay using the NIH 3T3 pooled stable cell lines.
Cells (3.0 3 103) were suspended in 1 ml of DMEM containing 10% FCS and
0.35% low gelling temperature agarose type VII (Sigma Cell Culture Reagents,
St. Louis, Mo.) and quickly plated in six-well dishes onto a hardened base layer
containing DMEM with 0.7% of agarose. Plates were fed with 1 ml of DMEM–
10% FCS–0.35% agar at weekly intervals. The number of colonies with more
than 30 cells was counted at 21 days. All the anchorage-independent growth
experiments were performed in triplicate.
MAP kinase activity. NIH 3T3 pooled stable cells were serum deprived for
16 h, washed twice with cold PBS, and then lysed in 1 ml of an ice-cold buffer
containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton
X-100, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM NaF, 100 mM
sodium orthovanadate, 10 mg (each) of aprotinin and leupeptin per ml, and 1
mM phenylmethylsulfonyl fluoride. Lysates were cleared by centrifugation at
13,000 3 g for 15 min at 48C, and the protein concentration in the supernatant
was determined using the micro-BCA protein assay reagent kit (Pierce). Aliquots
(100 mg) of cell protein were immunoprecipitated with an anti-p42ERK2 poly-
clonal antiserum (TR2; kindly provided by M. J. Weber, Charlottesville, Va.) for
2 h at 48C with stirring. The immunocomplexes were immobilized on protein
A-Sepharose beads (40 ml of packed beads per 1 ml of lysate; Pharmacia) and
washed extensively with lysis buffer followed by two washes with the kinase
reaction buffer (25 mM Tris-HCl [pH 7.4], 40 mM MgCl2, 1 mM DTT, 0.5 mM
EGTA). The kinase assay was carried out in 50 ml of kinase reaction buffer
containing 0.5 mg/ml of myelin basic protein (MBP) per ml, 200 mM ATP, and
3 mCi of [g-32P]ATP for 30 min at 308C. The reaction was stopped by adding 50
ml of Laemmli sample buffer, and proteins were electrophoresed on SDS–15%
polyacrylamide gels. Phosphorylated MBP was detected by autoradiography and
by counting Cerenkov emissions of the excised bands.
Analysis of kinetic parameters. Equal amounts (10 mg) of Tpr-Met, Tpr-Ron,
Tpr-Met.CR, and Tpr-Ron.CM cDNAs were transfected in COS-1 cells by the
DNA-calcium phosphate coprecipitation procedure. After 60 h of transient
transfection, the confluent cell cultures were placed on ice, washed twice with
cold PBS, and solubilized in 1 ml of ice-cold DIM buffer containing 1% Triton
X-100, 100 mM sodium orthovanadate, and inhibitors of proteases (aprotinin, 1
mg/ml; pepstatin, 50 mg/ml; leupeptin, 500 mg/ml; soybean trypsin inhibitor, 500
mg/ml; phenylmethylsulfonyl fluoride, 1 mM). Cell lysates were cleared by cen-
trifugation at 48C for 15 min at 13,000 3 g. The supernatants were immunopre-
cipitated with Sepharose-protein A (70 ml of packed beads per ml of lysate) and
with the relative antibodies (Ron antiserum was used at a concentration of 4 ml
of cell lysate per ml, while Met antiserum was used at 10 ml/ml) for 3 h at 48C
with stirring. To quantify the relative amounts of protein immunoprecipitated by
the same antibody from different samples, aliquots of immunocomplexes were
saved and analyzed by Western blotting. After immunoprecipitation, beads were
washed two times with lysis buffer and two times with the kinase buffer (25 mM
HEPES-NaOH [pH 7.4], 5 mM MnCl2, 100 mM DTT). The washed immuno-
complexes were divided into aliquots and used for the experiments. To evaluate
[Km (ATP)], the kinase reaction was performed in 30 ml of reaction buffer
supplemented with increasing concentrations of ATP (5, 10, 20, 40, and 80 mM)
in autophosphorylation experiments. A constant concentration of MBP exoge-
nous substrate (50 mM) was also present in exogenous substrate phosphorylation
experiments. To measure catalytic efficiency, the kinase reaction was performed
in the presence of increasing concentrations of MBP exogenous substrate (1.25,
2.5, 5, 10, and 20 mM) and of a constant concentration of ATP (100 mM). ATP
concentration was adjusted to a specific activity of 0.5 to 0.6 mCi/mmol with
[g-32P]ATP (Amersham). The range of ATP concentrations was determined by
serial dilutions, maintaining the specific activity unchanged. The standard reac-
tion time was 3 min at 48C, with continuous stirring both for autophosphorylation
and for exogenous substrate phosphorylation, as determined by preliminary
time-course experiments. The reactions were stopped by adding boiling Laemmli
buffer, and the eluted proteins were separated on SDS–8% polyacrylamide gels
(autophosphorylation) or on SDS–15% polyacrylamide gels (myelin basic pro-
tein phosphorylation), followed by autoradiography at 2708C with intensifying
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screens. Phosphate incorporation was estimated by scintillation counting of the
excised labeled bands in a Packard beta counter.
Biological assays. To avoid clonal variations, in our analyses we used pooled
populations of G418-selected NIH 3T3 cells as described above, rather than
isolated and specific clones for the different biological assays. Parallel cultures of
the NIH 3T3 cells stably transfected with the empty pSV2-neo vector were also
established as control cell lines. For growth rate experiments, pooled NIH 3T3
transfectants (3.0 3 103 cells per well) were plated at low serum concentration
(2% FCS) in 24-well plates, changing the medium every 2 days. Cell number was
estimated after staining with crystal violet by a colorimetric assay (28). For each
cell line and time point the experiments were conducted in quadruplicate. The
assays for motility and matrix invasion (1) were performed in blind-well Trans-
well chambers (Costar Corporation, Cambridge, Mass.). Briefly, 105 cells of each
NIH 3T3 pooled cell line were seeded on the upper side of a porous polycar-
bonate membrane (8.0-mm-pore size) coated (invasion assays) or not coated (cell
migration assays) with the artificial basement membrane Matrigel (12.5 mg per
filter; Collaborative Biomedical Products; Becton Dickinson Labware, Waltham,
Mass.). Only cells able to migrate or with an invasive phenotype are able to move
through the membrane and grow on the lower side of the filter. After 12 h of
incubation (for migration assays) or 36 h (for invasion assays), cells attached to
the upper side of the filters were mechanically removed, whereas cells that
migrated or invaded the Matrigel were fixed with glutaraldehyde and stained
with crystal violet. The stained cells that passed through the membrane pores
were solubilized in 10% acetic acid and absorbance at 595 nm was counted in a
microplate reader (Perkin-Elmer). Absorbance was converted into cell number
by reference to a stained cell concentration standard curve for each cell type.
Both assays were performed in the presence of low serum concentration (2%
FCS).
Tubulogenesis assay. Pooled G418-selected clones of MDCK cells expressing
Tpr-Met, Tpr-Ron, Tpr-Sea, Tpr-Ron.CM, and Tpr-Met.CR proteins at compa-
rable levels were used for the biological assay. For the cotransfection experi-
ments, two independent G418-selected clones of MDCK coexpressing Tpr-Met
and Tpr-Ron at comparable levels were used. Parallel MDCK cells stably trans-
fected with the empty vector were also established and used as control cell lines
(mock transfected). The morphogenetic activity of the MDCK cultures was
analyzed as described previously (33). Briefly, the cells were harvested from
cultures by using trypsin-EDTA and suspended at a concentration of 105 cells per
ml in collagen solution containing type I collagen gel (3 mg/ml; Collaborative
Biomedical Products; Becton Dickinson Labware), 103 DMEM (Gibco BRL),
and 0.5 M HEPES (pH 7.4). Aliquots (100 ml) of the cell suspension were
dispensed in microtiter 96-well plates and allowed to gel for about 15 min at 378C
before adding 200 ml of DMEM supplemented with 10% FCS. The medium was
changed every 2 days. After 7 to 10 days the morphogenic responses were
evaluated.
RESULTS
Tpr-Ron is a constitutively active tyrosine kinase. TPR-MET
results from a rearrangement between the 59 region of TPR
and the 39 region ofMET. In Tpr-Met the Met sequence starts
with an aspartic acid within the juxtamembrane domain. In the
rearranged viral ENV-SEA, the Sea sequence begins with the
same conserved aspartic acid residue. Thus, we generated re-
combinant Tpr-Ron and Tpr-Sea by using the same boundary
(Fig. 1A). The cDNAs were stably expressed in NIH 3T3
fibroblasts. To avoid clonal variations, all experiments were
performed on pooled G418-resistant colonies, rather than on
isolated clones. The expression of recombinant chimeras was
analyzed in stable transfectants by immunoprecipitation and
Western blotting, using excess C-terminal antisera to circum-
vent differences in affinity. All chimeras were found to be
expressed at comparable levels (Fig. 2A). The level of tyrosine
phosphorylation of the Tpr chimeras in intact cells was as-
sessed by immunoprecipitation followed by Western blotting
with antiphosphotyrosine antibodies. Their in vitro enzymatic
activities were examined by kinase assay. All chimeric proteins
showed high levels of autophosphorylation on tyrosine and
were capable of autokinase activity (Fig. 2A). The chimeric
proteins migrated according to an apparent molecular mass of
65 kDa for Tpr-Met and of 60 kDa for Tpr-Ron and Tpr-Sea.
These variations can be explained by differences in molecular
mass and/or by the presence of 14 potential phosphorylation
sites in Tpr-Met versus 12 in Tpr-Ron and Tpr-Sea. Phosphor-
ylation is known to influence protein migration in SDS-poly-
acrylamide gels.
Tpr-Ron does not transform rodent fibroblasts. Tpr-Met,
Tpr-Ron, and Tpr-Sea were tested in a focus-forming assay by
transfection in rodent fibroblasts. The efficiency of transfection
was assessed by cotransfection with pSV2-neo. The number of
G418-resistant colonies obtained was the same for the three
Tpr chimeras. Cells transfected with Tpr-Sea yielded a twofold
higher frequency of focus formation than those transfected
FIG. 1. (A) Schematic representation of the chimeric proteins containing
Tpr and the intracellular domains of Met, Ron, and Sea. The leucine zipper
motifs (LZipA and LZipB) and the receptor intracellular subdomains are indi-
cated at the top. Fusion with Tpr occurs at an aspartic acid residue (D), con-
served in Met, Ron, and Sea. The two neighboring tyrosine residues (Y) of the
kinase domains, corresponding to the major autophosphorylation site and the
tyrosine of the C-terminal tails in the conserved bidentate multifunctional dock-
ing site, are shown. (B) Schematic representations of Tpr-Met and Tpr-Ron
swapped chimeras. Acronyms on the right identify the different constructs. In the
upper two constructs, the juxtamembrane (J) subdomains are replaced. Tpr-
Met.JR contains the Ron juxtamembrane subdomain and Tpr-Ron.JM contains
that of Met. In the middle two constructs the carboxy-terminal (C) tails are
exchanged. Tpr-Met.CR contains the Ron tail and Tpr-Ron.CM contains that of
Met. In the lower two constructs the kinase (K) domains are exchanged. Tpr-
Met.KR contains the kinase domain of Ron and Tpr-Ron.KM contains that of
Met. The Tpr, Met, and Ron sequences are identified by hatched, white, and
black areas, respectively.
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with Tpr-Met. Unexpectedly, Tpr-Ron was completely unable
to induce foci of transformation (Fig. 2B). Selected clones of
transfected cells, expressing levels of Tpr-Ron at least three-
fold over the unselected population pool, did not form foci at
confluence. This ruled out the possibility that lack of transfor-
mation was due to low expression of the chimeric protein.
As an alternative approach to investigate the transforming
potential of the MET gene family, we performed anchorage-
independent growth assays on fibroblasts expressing the three
Tpr-chimeras. Tpr-Met stable transfectants grew in soft agar,
yielding a significant number of colonies. Tpr-Sea transfectants
yielded twice as many colonies. In contrast Tpr-Ron transfec-
tants failed to develop anchorage-independent colonies (Table
1).
Tpr-Ron activates the mitogenic pathway. Cell transforma-
tion requires a strong mitogenic signal for which MAP kinase
phosphorylation is a mandatory step (7). MAP kinase activa-
tion in pooled stable NIH 3T3 transfectants was analyzed by
measuring phosphorylation of an exogenous substrate after
immunoprecipitation with anti-MAP kinase antibodies (Fig.
3). In cells expressing Tpr-Sea and Tpr-Met, the MAP kinase
was activated seven- and sixfold over the background, respec-
FIG. 2. Constitutive activation and transforming ability of the Tpr chimeras. (A) Protein expression, in vivo autophosphorylation, and in vitro tyrosine kinase activity
of Tpr-Met, Tpr-Ron, and Tpr-Sea. The specific chimeras were analyzed by immunoprecipitation and Western blotting with antibodies against the C-terminal domains
of Met, Ron, and Sea (Protein expression) and with anti-phosphotyrosine antibodies (Tyr-phosphorylation). The in vitro tyrosine kinase activity of the chimeras was
tested by incubating specific immunoprecipitates with [g-32P]ATP (In vitro autophosphorylation). (B) Focus-forming assay of rodent fibroblasts transfected with the
three Tpr chimeras. Tpr-Met showed a focus-forming activity of 290 6 30 foci per 10 mg of cDNA transfected. Tpr-Sea induced twice as many foci as Tpr-Met. No
foci were scored in Tpr-Ron or cells transfected with vector alone. Dishes were stained with crystal violet. The figure is representative of at least three independent
transfections performed in triplicate.
TABLE 1. The in vitro transforming ability of Tpr-Met, Tpr-Ron,
and Tpr-Sea




Tpr-Met 12 6 3 1.00
Tpr-Ron ,1 ,0.01
Tpr-Sea 29 6 3 1.92
Tpr-Met.CR 28 6 2 1.96
Tpr-Ron.CM ,1 ,0.01
Tpr-Met.JR 11 6 3 0.95
Tpr-Ron.JM ,1 ,0.01
Tpr-Met.KR ,1 ,0.01
Tpr-Ron.KM 26 6 1 1.90
a Cells were seeded at a density of 3.0 3 103 per well, and the number of
colonies (.30 cells in size) was scored after 3 weeks. Numbers indicate the
averages (6 standard deviation) of three independent experiments performed in
triplicate.
b Values were determined as ratios between the number of observed foci and
the number of G418-resistant colonies. The values were normalized to the
focus-forming activity of Tpr-Met, which was set at 1.00. Numbers were calcu-
lated from the results of at least three independent transfections of each con-
struct.
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tively, while expression of Tpr-Ron resulted in only a modest
increase of MAP kinase activity. This MAP kinase stimulation,
however, was significant and correlated with induction of cell
proliferation (Fig. 4). Cells expressing Tpr-Met or Tpr-Sea
acquired a transformed behavior characterized by unrestrained
proliferation. Cells expressing Tpr-Ron were able to grow in
low serum, but their growth was arrested when saturation den-
sity was reached (contact-arrested condition). Tpr-Met- and
Tpr-Sea-transformed cells were spindle shaped, elongated, and
highly refractile. Cells expressing Tpr-Ron were poorly refrac-
tile and highly adherent, typical of normal fibroblasts (unpub-
lished data).
Transformation is linked to the functional features of ki-
nase domains. To understand why constitutive activation of
Ron does not result in cell transformation we swapped specific
Ron subdomains with the corresponding Met regions. The
Ron subdomains exchanged with Met were (i) the juxtamem-
brane domain (amino acids [aa] 1027 to 1085), which contains
several serine residues, putative targets for negative regulation
(11); (ii) the kinase domain (aa 1085 to 1352); and (iii) the
carboxy-terminal tail (aa 1353 to 1400), which includes the
multifunctional docking site essential for signal transduction
(37). The structure of the swapped recombinant proteins and
the acronyms used to identify them are illustrated in Fig. 1B.
The recombinant proteins were all expressed with the same
efficiency, were equally capable of autophosphorylation on ty-
rosine in vivo, and displayed comparable kinase activity in vitro
(Fig. 5A).
The transforming potential of swapped Tpr chimeras was
analyzed in focus-forming and soft agar growth assays. Substi-
tution of the Ron juxtamembrane domain with that of Met
(Tpr-Ron.JM) did not confer transforming ability to Tpr-Ron.
In the complementary experiments, the transforming ability of
Tpr-Met was unchanged by the replacement of its juxtamem-
brane subdomain with that of Ron (Tpr-Met.JR). Replacement
of the Ron carboxy-terminal tail with that of Met (Tpr-
Ron.CM) did not confer transforming ability to Tpr-Ron. Un-
expectedly, the mirror construct Tpr-Met, containing the car-
boxy-terminal tail of Ron (Tpr-Met.CR), yielded a twofold
higher number of foci. These results were confirmed by similar
chimeras for which the tyrosine kinase was the domain being
swapped. The Tpr-Met construct having its kinase domain
replaced by that of Ron (Tpr-Met.KR) did not induce foci of
transformation. Conversely, Tpr-Ron under the control of the
Met kinase was as active as Tpr-Met.CR (Fig. 5B).
Similar results were obtained when the swapped chimeras
were tested for anchorage-independent growth (Table 1). Al-
together, these experiments show that the transforming ability
of Tpr-Ron and Tpr-Met is linked to their kinase domains,
whose intrinsic properties must be different.
Catalytic efficiency of the Ron kinase. To evaluate the cat-
alytic efficiency of Tpr-Met and Tpr-Ron we determined the
kinetic parameters for tyrosine autophosphorylation and for
phosphorylation of the exogenous substrate MBP. The assays
were performed in the presence of 5 mM Mn21 (35) at time
points and temperatures optimized for a linear response, as
described in Materials and Methods.
The apparent Michaelis-Menten constants [Km (app)] of
Tpr-Met and Tpr-Ron for ATP were found similar both in
autophosphorylation (2.36 6 1.0 mM and 2.32 6 0.5 mM,
respectively) and in phosphorylation of the MBP exogenous
substrate (10.0 6 0.5 mM and 10.6 6 0.6 mM, respectively).
These values are in the same range as those previously pub-
lished for the full-size Met receptor kinase (35) and for the
full-size Ron receptor (unpublished data).
Similarly, the apparent Michaelis-Menten constant of Met
and Ron kinases for MBP was in the same order of magnitude
(Table 2).
However, when the Vmax (maximum rate of metabolism) for
MBP exogenous substrate phosphorylation was measured, a
significant difference between the Met kinase and the Ron
kinase was observed. The catalytic efficiency of the Ron kinase,
calculated as Vmax/Km (24), was found to be five times lower
than the efficiency of the Met kinase (Table 2). Tpr-Met was
FIG. 3. MAP kinase activation by Tpr-Sea, Tpr-Ron, and Tpr-Met. The assay
was performed by measuring the amount of 32P transferred to myelin basic
protein (MBP) by MAP kinase immunoprecipitated with anti-p42ERK2 antibod-
ies. MAP kinase activation is expressed as fold increase over the background in
triplicate determinations (bars 5 standard deviations). Tpr-Sea and Tpr-Met
showed more than a twofold increase over Tpr-Ron in MAP kinase activation.
FIG. 4. Cell proliferation induced by Tpr-Met, Tpr-Ron, and Tpr-Sea. NIH
3T3 cells expressing the Tpr chimeras were grown in low serum concentration
(2% FCS). The cell number was evaluated by absorbance (A595) of monolayer
stained with crystal violet and solubilized. The data shown are the averages
(bars5 standard deviations) of replicate wells (n5 3) from a typical experiment.
Cells expressing transforming Tpr-Met (F) and Tpr-Sea (n) displayed a fast and
unrestrained proliferation. Cells expressing Tpr-Ron (h) showed an increased
growth rate over the vector-alone control cells (E) and reached a saturation
density, corresponding to a contact-arrested condition. These data are represen-
tative of at least three independent experiments.
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compared with the swapped chimera bearing the Ron kinase
domain fused with the tail of Met (Tpr-Ron.CM) and Tpr-Ron
was compared with that bearing the Met kinase fused with the
tail of Ron (Tpr-Met.CR). This rules out the possibility that the
observed values reflected differences in affinities of the anti-
Met and anti-Ron antisera used to immunoprecipitate the ki-
nases, as in the case of the direct comparison between Tpr-Met
and Tpr-Ron.
The kinetic curves showed that the reactions catalyzed by
the two Tpr chimeras bearing the Ron kinase (Tpr-Ron and
Tpr-Ron.CM) attained saturation values consistently lower
than those reached by the Met kinase (Fig. 6).
Activation of Ron induces an invasive phenotype. As shown
above, constitutive activation of Ron triggers the MAP kinase
pathway and cell proliferation but not transformation. We next
FIG. 5. Constitutive activation and transforming ability of the swapped chimeras between Tpr-Met and Tpr-Ron. (A) Protein expression, in vivo autophosphor-
ylation, and in vitro tyrosine kinase activities of Tpr-Met and Tpr-Ron swapped chimeras. The specific chimeras were analyzed by immunoprecipitation and Western
blotting with antibodies against the C-terminal domains of Ron (Tpr-Met.CR, Tpr-Ron.JM, and Tpr-Ron.KM) and Met (Tpr-Ron.CM, Tpr-Met.JR, and Tpr-Met.KR)
(Protein expression) and with anti-phosphotyrosine antibodies (Tyr-phosphorylation). The in vitro tyrosine kinase activity of the chimeras was tested by incubating
specific immunoprecipitates with [g-32P]ATP (In vitro autophosphorylation). (B) Focus-forming assay of rodent fibroblasts transfected with the swapped chimeras.
Tpr-Met.CR and Tpr-Ron.KM induced twice as many foci as Tpr-Met.JR. No foci were scored in Tpr-Ron.JM, in Tpr-Ron.CM, and in Tpr-Met.KR transfected cells.
Dishes were stained with crystal violet. The figure is representative of at least three independent transfections, performed in triplicate.






Tpr-Met 1.76 6 0.5 1.15 6 0.07 0.65
Tpr-Ron.CM 1.79 6 0.3 0.24 6 0.01 0.13
Tpr-Ron 1.67 6 0.5 0.44 6 0.04 0.26
Tpr-Met.CR 2.00 6 0.2 2.46 6 0.07 1.23
a Kinase assays were carried out on immunocomplexes, in the presence of
increasing concentrations of MBP and of a constant concentration of ATP, as
described in Materials and Methods. The kinase affinity for MBP [Km (app)] and
the phosphorylation maximal rate [Vmax (app)] are indicated. The ratio Vmax
(app)/Km (app) represents the catalytic efficiency of the enzyme.
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investigated the other arm of the biological response: cell dis-
sociation, motility, and invasiveness.
MDCK (Madin-Darby canine kidney) cells in cultures form
tight epithelial monolayers with junctional complexes. HGF-
induced activation of Met in these cell causes the breakdown of
intercellular junctions and the transition to a fibroblastoid
morphology, followed by cell motility (55). Expression of Tpr-
Ron in MDCK cells resulted in a constitutive scattered phe-
notype (Fig. 7). The same phenotype was observed upon trans-
fection of Tpr-Met and was indistinguishable from that
occurring in MDCK cells bearing an HGF-dependent auto-
crine circuit (58). In contrast, Tpr-Sea did not induce any
constitutive cell scattering (unpublished data).
NIH 3T3 fibroblasts expressing Tpr-Ron showed enhanced
migration through 8.0-mm-pore-size polycarbonate filters.
These cells were also capable of invasive migration through an
artificial basement membrane made mainly of laminin, colla-
gen IV, and heparan sulfate (Matrigel) (1). The cell migration
and matrix invasion rates were comparable to those induced by
transfection of Tpr-Met. Interestingly, cells expressing Tpr-Sea
displayed only a modest increase in cell motility as well as in
matrix invasion with respect to controls (Fig. 8).
These data demonstrate that constitutive activation of Ron,
despite the low efficiency of its kinase, steers cells toward
unrestricted cell dissociation, migration, and invasion.
Tpr-Ron induces unbranched tubulogenesis. MDCK cells
are a sensitive target for signals controlling polarized growth.
When stimulated in vitro by HGF or MSP, they migrate in
tridimensional collagen gels and form long and branched tu-
bules (32, 33).
MDCK cells expressing Tpr-Ron, seeded in tridimensional
collagen gels, formed round cystic colonies within 3 to 5 days.
Thereafter, the cysts developed a few spikes which, in a week,
evolved into long tubular structures. Interestingly, these tu-
bules never branched, unlike those observed in mock-trans-
FIG. 6. Phosphorylation kinetics of the Ron (F and n) and Met (E and h)
kinases in the presence of increasing concentrations of exogenous substrate
(MBP). To immunoprecipitate identical amounts of active kinase, the swapped
chimeras were used. Tpr-Ron (n) and Tpr-Met.CR (h) were immunoprecipi-
tated with anti-Ron antibodies; Tpr-Met (E) and Tpr-Ron.CM (F) were immu-
noprecipitated with anti-Met antibodies. The Vmax of the phosphorylation reac-
tion by the Met kinase is fivefold higher than that of the Ron kinase. Plotted
values are means of triplicate determinations (error bars). The kinetic curves
were calculated by using a curve-fitting computer program for the Michaelis-
Menten equation (GraFit; Microsoft).
FIG. 7. Expression of Tpr-Met and Tpr-Ron in MDCK cells induces constitutive scattering. (A) Mock-transfected MDCK cells form tightly packed islands. (B) The
islands dissociate and scatter in the presence of HGF (50 ng/ml). (C) MDCK cells express constitutively activated Tpr-Ron. (D) MDCK cells express constitutively
activated Tpr-Met. Pictures were taken at the same magnification. Scale bar, 100 mm.
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fected cells stimulated with HGF. On the other hand, MDCK
cells expressing Tpr-Met and Tpr-Sea grew as larger spherical
cysts, which never evolved into tubular structures. Also, the
Tpr-Met.CR chimera did not induce tubules in MDCK cells,
but formed large cysts as well, whereas the counterpart con-
struct, Tpr-Ron.CM, led to unbranching morphogenesis, as did
Tpr-Ron.
Moreover, MDCK cells cotransfected with Tpr-Met and
Tpr-Ron constructs developed typical cystic structures with
outward-projecting spikes. These spikes never developed a tu-
bule formation (Fig. 9).
These data demonstrate that constitutive activation of Ron
and Met kinases differentially induces the morphogenic pro-
gram, independently from the nature of the transducing mul-
tifunctional docking sites.
DISCUSSION
Ligand-dependent activation of the Ron receptor induces
cell proliferation under physiological conditions (13, 32, 59).
However, naturally occurring oncogenic counterparts of RON
have not been identified so far, nor is it known if RON has
transforming potential in experimental conditions. Here we
show that constitutive activation of the Ron tyrosine kinase,
obtained by fusion with Tpr, stimulates MAP kinase and cell
growth but does not transform NIH 3T3 fibroblasts. Since
Tpr-Met is instead a powerful oncogene, we used chimeras
obtained by swapping subdomains to identify the structural
features responsible for this difference in transforming ability.
Transforming assays performed on Tpr-Met and Tpr-Ron ki-
nase-swapped chimeras indicate that the lack of Ron onco-
genic potential is intrinsic to its tyrosine kinase domain. The
integrity of the glycine loop motif involved in ATP binding is
known to be critical for transformation mediated by p60c-src
and ErbB (27, 47). For this reason, we tested the affinity of
Tpr-Ron and Tpr-Met for ATP binding. Their Km (ATP) val-
ues were found to be comparable.
There are several reports showing that the oncogenic poten-
tial of a tyrosine kinase is dramatically influenced by differ-
ences in the catalytic efficiency. In the case of the EGF recep-
tor the transforming potential is unleashed by a single point
mutation in the kinase domain, responsible for increased cat-
alytic activity (48). The transforming properties of a number of
pp60c-srcmutants directly correlate with the degree of elevation
of their catalytic activities (26). Moreover, the proto-oncogene
Neu shows a lower Vmax with respect to its oncogenic counter-
part (29). Finally, the EGF receptor kinase has a Vmax that is
only threefold lower than the Vmax of the oncogenic v-erbB
(34). The reported data show that the catalytic efficiency of
Tpr-Ron, expressed as a ratio between the Vmax and the Km
(MBP), is five times lower than the Vmax of Tpr-Met. This
suggests that catalytic efficiency may be the parameter that
discriminates between the oncogenic potentials of the two ki-
nases.
As an estimate of the overall signalling ability of Tpr-Ron in
vivo, we determined the level of activation of the MAP kinase
cascade in NIH 3T3 cells stably expressing the three constructs.
The total MAP kinase activity in cells expressing Tpr-Ron was
significantly lower than that measured in cells expressing Tpr-
Met and Tpr-Sea. This indicates that, in spite of the presence
of an optimal multifunctional docking site, the relatively low
catalytic efficiency of Tpr-Ron results in less effective signal-
ling. We conclude that the downstream signalling cascade ini-
tiated by the permanently activated Ron, unlike that triggered
by activation of Met and Sea, cannot overcome the negative
mechanisms regulating growth at confluence and cannot sus-
tain the critical threshold necessary for a fully transformed
phenotype, at least in the system studied here. However, we
cannot exclude the possibility that the RON gene displays
transforming potential in other cell types, such as hemopoietic
or neuroendocrine lineages that are known to express the Ron
protein and that might respond to a lower threshold of MAP
kinase signaling.
It has been demonstrated that quantitative differences in
MAP kinase activation result in qualitative differences in gene
expression and, consequently, in distinct biological responses
(proliferation versus differentiation; 31). The intensity and du-
ration of MAP kinase activation determine the different levels
of phosphorylation and activation of transcription factors (9,
56, 57). An example of how the intensity of intracellular signals
can produce large differences in transcriptional responses is
given by the tyrosine kinase receptor Toll (44). Its differential
activation leads to the generation of dorsoventral polarity in
Drosophila embryos by controlling phosphorylation of the tran-
scriptional factor dorsal at different levels (23, 54).
We ruled out the possibility that Tpr-Ron signaling involves
specific effectors different from those recruited by Tpr-Met on
the basis of the experiments performed with the C-terminal
swapped chimeras. Surprisingly, the Ron C-terminal tail was
FIG. 8. Motility and matrix invasion of NIH 3T3 cells expressing Tpr chime-
ras. (A) Cell migration through 8.0-mm-pore-size filters of the Transwell cham-
ber. (B) Cell invasiveness measured as migration through the filters coated with
a reconstituted basement membrane made of laminin, collagen IV, and heparan
sulfate. Controls were cells transfected with an empty vector (mock). Cell mi-
gration and invasiveness were expressed as the percentages of input cells that
have migrated or have invaded the artificial basement membrane. Bars indicate
the standard deviations of three independent experiments.
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found to be even better than the Met tail in inducing cell
transformation. The Ron tail includes the conserved multi-
functional docking site (Y-1353 VQL-X3-Y-1360 MNL) that
binds in vitro the same set of SH2-containing signal transduc-
ers bound by Met (Y-1349 VHV-X3-Y-1356 VNV) (37). It has
been shown that the transforming potential of Tpr-Met corre-
lates with the level of Met-mediated Ras activation, which in
turn depends on the ability to bind Grb-2 (10, 38). The Met
receptor binds Grb-2 and activates the Ras guanyl-nucleotide
exchanger Sos (18) through the Y-1356 VNV sequence (i.e.,
FIG. 9. Growth in tridimensional collagen matrix of MDCK cells expressing Tpr-Ron and Tpr-Met. (A) Mock-transfected cells growing as spherical cysts. (B)
Mock-transfected cells in the presence of 100 ng of HGF per ml. Branching tubular structures are observed (arrows). (C, E, and G) Cells expressing Tpr-Met, Tpr-Sea,
and Tpr-Met.CR, respectively. Formation of tubules is completely inhibited. (D and F) Cells expressing Tpr-Ron and Tpr-Ron.CM, respectively, forming long and
unbranched tubules. (H) Cells coexpressing Tpr-Met and Tpr-Ron. Few spikes projecting outward never developed tubular structures. Micrographs of representative
fields were taken 1 week after seeding single-cell suspensions. Scale bar, 100 mm.
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the phosphotyrosine followed by an asparagine residue in the
12 position) (37). Similarly, the Ron tail can recruit the Grb-
2-Sos complex (30) through Y-1360 MNL (53). The reason for
the enhanced efficiency of transformation displayed by the Ron
tail (once fused to Tpr-Met) is thus not easily explained. The
tyrosine of the Ron Grb-2 binding site may be a better sub-
strate for phosphorylation than the corresponding tyrosine of
Met, as it is followed by a residue with a larger hydrophobic
side chain at the 11 position (Y-1360 MNL; 51). On the other
hand, Tpr-Sea had a transforming ability better than Tpr-Met.
In this case the reason for this behavior is provided by the
presence of a duplicated Grb-2 binding site in its C-terminal
tail (Y-1360 VNL-X3-Y-1367 VNL). According to this hypoth-
esis, it has been demonstrated that duplication of the Grb-2
binding site in Tpr-Met causes signalling reinforcement along
the Ras pathway and enhances transformation (38).
Tpr-Ron may fail to transform host cells by its subcellular
localization which is cytoplasmic, whereas the intact Ron re-
ceptor is located on the plasma membrane. This could lead to
interaction with a different set of signalling and regulatory
molecules, lacking the critical ones located in the inner face of
the plasma membrane. This is however unlikely since Tpr-Met,
which is cytoplasmic as well, is a powerful transforming agent.
Moreover, we recently isolated a naturally occurring Ron vari-
ant, originated by alternative splicing, whose tyrosine kinase is
activated by thiol-mediated oligomerization: this variant fails
to transform fibroblasts in spite of its membrane localization
(4).
Constitutive activation of Tpr-Ron, while inefficient in trans-
formation did trigger a genetic program leading to the acqui-
sition of an invasive phenotype. This program includes cy-
toskeletal reorganization, loss of intercellular junctions, cell
dissociation (scattering) followed by active migration, and in-
vasion of extracellular matrices (16, 55, 61). It has been shown
that cell scattering is dependent on activation of Ras and Rac
with concomitant inhibition of Rho (21, 40) and also requires
phosphatidylinositol 3-kinase (PI 3-kinase) activation (8, 43).
The Ras threshold required for the scattering response is by far
lower than that necessary for growth and transformation (38).
Tpr-Ron, in spite of its weak kinase, fulfills the requirements
for activating cell scattering and matrix invasion and provides
a naturally occurring example of dissociation between the two
arms of the biological response triggered by the Met family of
receptors.
The Ron and Met receptors, after controlled activation by
their respective ligands, drive epithelial cells to migrate into
collagen matrices, to proliferate, and to polarize. This complex
regulation results in the formation of branched tubular struc-
tures (20). Tpr-Ron appears to be able to drive part of this
program, inducing linear tubulogenesis but not branching. An
interpretation of the failure of Tpr-Ron to complete tubulo-
genesis could be the cytosolic compartmentalization of the
chimera that may alter the interactions with membrane-asso-
ciated signal transducers. On the contrary, uncontrolled acti-
vation of Tpr-Met in MDCK cells boosts cell proliferation, as
shown by the formation of larger spherical cysts, but fails to
activate the morphogenic program. This is not in contrast to
the constitutive scattering phenotype in these cells, since tu-
bulogenesis is a complex mechanism based on the activation of
multiple specific genes (3), while cell scattering is elicited by
short-term signalling and is independent from RNA synthesis
(40). The C-terminal swapped chimeras between Tpr-Met and
Tpr-Ron indicate that the morphogenic phenotype is con-
trolled exclusively by the intensity of the signal, rather than by
specific signal transduction pathways. A potential explanation
for the behavior of the Met kinase-based constructs could be
that the high level of signalling conveyed by the Met kinase,
optimal to induce unrestrained proliferation, interferes with
the accomplishment of the morphogenic program. On the
other hand, the low signalling threshold attained by the Ron
kinase seems permissive and adequate to activate at least part
of the morphogenic program. This can be explained by differ-
ential activation of critical genes due to a lower dosage of
transcriptional activators induced by Ron. Interestingly, when
MDCK cells are transfected with both Tpr-Met and Tpr-Ron
constructs, the tubulogenesis is suppressed even in the pres-
ence of an active Tpr-Ron kinase. This suggests that the mi-
togenic signals elicited by the Met kinase are somehow domi-
nant on the morphogenic signals elicited by Tpr-Ron.
In contrast with the above, Tpr-Sea, which was better than
Tpr-Met in inducing transformation, elicited neither a fully
invasive phenotype nor tubule formation. The docking site of
Sea is made of two identical Y*VNL sequences, which can
both bind Grb-2 at high affinity. This may prevent recruitment
of the necessary amount of PI 3-kinase for promoting motility,
invasion, and tubule formation. This is confirmed by recent
data from our laboratory, obtained with a Tpr-Met mutant
binding two Grb-2 molecules (and thus superactivating the Ras
pathway) but lacking binding to PI 3-kinase. This mutant trans-
formed the host cells with higher efficiency but was unable to
trigger matrix invasion and metastasis, indicating that concom-
itant activation of the two pathways is necessary for the fully
malignant phenotype (2, 15). Moreover, it has been shown that
the lack of a functional PI 3-kinase binding site impairs the
morphogenic response (8). Interestingly, in the tail of the nat-
urally occurring aggressive oncogene v-sea (50) a C/A trans-
version substitutes the leucine residue at 13 to the first ty-
rosine (Y-1360) with a methionine residue, creating an optimal
consensus for PI 3-kinase (Y-1360 INM), which may compen-
sate for the presence of the asparagine residue at 12 (52).
Taken together, the data reported show that the RON gene
codes for a potentially harmful receptor which may transduce
invasive-metastatic signals but is hampered by an inefficient
kinase domain. This suggests a possible role for activated Ron
in tumor progression (late steps of malignancy) rather than in
the early steps of the tumorigenic process.
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